Vivos Therapeutics, which is commercializing non-invasive medical devices for sleep disordered breathing, raised $21 million by offering 3.5 million shares at $6, within the range of $5 to $7. The company offered 0.2 million more shares than anticipated. At pricing, the company raised 5% more in proceeds than expected and commands a fully diluted market value of $110 million.
Vivos Therapeutics plans to list on the Nasdaq under the symbol VVOS. Roth Capital acted as a lead manager on the deal.
